10 Melanoma Clinical Trials in Pittsburgh, PA (2026)

Q: How do I join a clinical trial in Pittsburgh?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you.

Recruiting Melanoma Studies in Pittsburgh

NCT04114136Recruiting

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Ade...

Pittsburgh, PAPHASE272 participantsDan Zandberg

View Study Details

NCT05361174Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC)....

Pittsburgh, PAPHASE153 participantsIovance Biotherapeutics, Inc.

View Study Details

NCT04572451Recruiting

Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Nivolumab (and other agents affecting the anti-programmed death-1 \[anti-PD-1\] pathway) have demonstrated anti-tumor activity in multiple tumor types. Combinations of immune-oncology (IO) agents with...

Pittsburgh, PAPHASE150 participantsYana Najjar

View Study Details

NCT06831071Recruiting

Evaluation of Hypoxia in Primary Melanoma

When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumo...

Pittsburgh, PA50 participantsYana Najjar

View Study Details

NCT06070012Recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating...

Pittsburgh, PAPHASE244 participantsDiwakar Davar

View Study Details

NCT06599619Recruiting

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as...

Pittsburgh, PA30 participantsJohn Kirkwood

View Study Details

NCT06216938Recruiting

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) virus, with potential oncolytic, immunostimulating and...

Pittsburgh, PAEARLY_PHASE125 participantsYana Najjar

View Study Details

NCT04658303Recruiting

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Melanoma in-transit metastases (ITMs) continue to represent a therapeutic dilemma, in that no standard method of treatment has been uniformly adopted. The complexity and heterogeneity of patient and d...

Pittsburgh, PA20 participantsYana Najjar

View Study Details

NCT07223411Recruiting

Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with ...

Pittsburgh, PA20 participantsJohn Kirkwood

View Study Details

NCT07286318Recruiting

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Organ Transplant Recipients This study is designed to evaluate whether a topical 5% niacinamide cream can help pr...

Pittsburgh, PAEARLY_PHASE120 participantsMarissa Lobl

View Study Details

About Melanoma Clinical Trials in Pittsburgh

Melanoma is the most serious type of skin cancer, developing from the pigment-producing cells known as melanocytes. While less common than other skin cancers, melanoma is more likely to spread. Immunotherapy and targeted therapy have revolutionized melanoma treatment.

There are currently 10 melanoma clinical trials recruiting participants in Pittsburgh, PA. These studies are seeking a combined 384 participants. Research is being sponsored by Dan Zandberg, Iovance Biotherapeutics, Inc., Yana Najjar and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Melanoma Clinical Trials in Pittsburgh — FAQ

Are there melanoma clinical trials in Pittsburgh?

Yes, there are 10 melanoma clinical trials currently recruiting in Pittsburgh, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Pittsburgh?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Pittsburgh research site will contact you about next steps.

Are clinical trials in Pittsburgh free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Pittsburgh studies also compensate for your time and travel.

What melanoma treatments are being tested?

The 10 active trials in Pittsburgh are testing new therapies including novel drugs, biologics, and treatment approaches for melanoma.

Data updated July 16, 2026 from ClinicalTrials.gov